Vaxine: leading the way in developing novel vaccines to improve global health

Swine Flu Vaccine Breakthrough

In July 2009 Vaxine commenced a clinical trial of the world's first adjuvanted recombinant H1N1/2009 (swine flu) vaccine, developed as a partnership between Vaxine and Protein Sciences Corporation, a Meriden, USA, based biotechnology company specialising in production of recombinant proteins using insect cell lines. The swine flu vaccine trial was successfully completed in October 2009 and the trial results have been submitted for publication.